Goniotomy

3

Review clinical trials related to Goniotomy. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Goniotomy in Primary Congenital Glaucoma

Brief Summary This is a multicenter cohort study designed to evaluate and compare the efficacy and safety of different surgical extents of goniotomy (GT) - specifically 120°, 240°, and 360° - in the treatment of Primary Congenital Glaucoma (PCG). The study incorporates both retrospective and prospective patient enrollment. PCG is a rare, severe, and blinding childhood eye disease for which surgery, particularly angle surgery, is the primary treatment. Goniotomy, a minimally invasive glaucoma surgery (MIGS), is increasingly used. However, the optimal extent of the angle incision remains uncertain, with limited and conflicting evidence comparing different ranges. The study plans to enroll a total of 120 PCG patients, dividing them into three groups based on the surgical extent received (120°, 240°, or 360°). Patients will be recruited from participating ophthalmic centers across China. The study does not involve interventional assignment; grouping is based on the actual procedure performed as part of standard care. The primary outcome measure is the qualified surgical success rate post-operatively, defined as intraocular pressure (IOP) ≤21 mmHg (with or without medication), without vision-threatening complications or the need for further glaucoma surgery. IOP will be measured by Goldmann or iCare tonometry. Secondary outcomes include various safety indicators such as intraoperative and postoperative complications, the number of intraocular pressure-lowering medications required, visual acuity, and the need for further surgery. The study aims to generate comparative evidence to inform clinical decision-making, potentially contributing to optimized surgical guidelines for PCG treatment.

Participants needed: 120
Trial details
Biological sex: AllType: ObservationalSponsor: Sun Yat-sen UniversityUpdated: Apr 24, 2026Locations: 1
Eligibility criteria

Diagnosis of primary congenital glaucoma (PCG). [+4]

Concomitant other ocular diseases: including but not limited to diabetic retinop... [+3]

Status: Recruiting

Biometric Changes After Intervention of Anterior Chamber Angle : an Observational Study

The drainage angle in the anterior chamber of the eye mediates the outflow of aqueous humor, and pathological changes here can lead to high intraocular pressure and glaucoma. Minimally invasive glaucoma surgery, particularly angle surgery, has advanced recently, allowing clear visualization of angle structures like the trabecular meshwork and Schlemm's canal using surgical goniolens. Techniques for angle intervention include widening the angle, reopening closed angles, and rebuilding outflow pathways using methods such as laser peripheral iridotomy, Argon laser peripheral iridoplasty, and mechanical separation of adhered tissues. Our research team plans to conduct imaging studies to track the healing of angle tissues post-surgery, aiming to support innovation and standardization of minimally invasive angle surgery.

Participants needed: 300
Trial details
Age: 30-85Biological sex: AllType: ObservationalSponsor: Zhongshan Ophthalmic Center, Sun Yat-sen UniversityUpdated: Dec 12, 2025Locations: 1
Eligibility criteria

Glaucoma patients eligible for standalone or combined angle intervention surgeri... [+2]

Patients with severe ocular conditions such as corneal infection, ulcer, trauma,... [+5]

Status: Recruiting

Evaluation of Phacogoniotomy in Medically-controlled POAG

The goal of this multicenter non-inferiority randomized controlled trial is to compare the efficacy of phacoemulsification with intraocular lens implantation (PEI) combined with goniotomy (GT) and PEI combined with medical therapy (MED) in the treatment of medically-controlled primary open-angle glaucoma (POAG) with cataract. The main questions it aims to answer are: * Whether the PEI+GT was non-inferior to PEI+MED with regard to the intraocular pressure lowering effect in medically-controlled POAG. * Whether the PEI+GT has value of health economics. Participants will be randomized to receive either PEI+GT or PEI+MED, and followed up with a 1-year period as a primary outcome.

Participants needed: 100
Trial details
Age: 40-85Biological sex: AllType: InterventionalSponsor: Sun Yat-sen UniversityUpdated: Dec 11, 2024Locations: 1
Eligibility criteria

40 ≤ Age ≤ 85 years, gender unrestricted. [+5]

Any history of intraocular surgery or ocular trauma. [+7]